Guggenheim Initiates Coverage On Praxis Precision Medicine with Buy Rating, Announces Price Target of $155
Portfolio Pulse from Benzinga Newsdesk
Guggenheim has initiated coverage on Praxis Precision Medicine (NASDAQ:PRAX) with a Buy rating and set a price target of $155.
June 18, 2024 | 10:37 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Guggenheim has initiated coverage on Praxis Precision Medicine with a Buy rating and a price target of $155, indicating strong confidence in the company's future performance.
The initiation of coverage with a Buy rating and a high price target of $155 by a reputable analyst from Guggenheim is likely to boost investor confidence and drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100